Manuscripts
Showing 1526 manuscripts.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
Citation
Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Emily Brown, Kayla Denson, Bobbie Graham, Laura Hovind, Thucuma Sise, Hedy Teppler, Sisinyana Ruth Mathiba, Lee Fairlie, Jana L Winckler, Gretchen Slade, Tammy Meyers, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of Pediatric Infectious Disease Society. 2021. PMID: 32448902Year
2020
Journal
Journal of Pediatric Infectious Disease Society
Study
P1101
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age
Citation
Jane C Lindsey, Denise L Jacobson, Hans M Spiegel, Catherine M Gordon, Rohan Hazra, George K K Siberry. Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. Clinical Infectious Diseases. 2021. 72: 1059-1063. PMID: 32584996Year
2022
Journal
Clinical Infectious Diseases
Study
P1076
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097
Citation
Diana F Clarke, Jos Lommerse, Edward P Acosta, Mae P Cababasay, Jiajia Wang, Stephen A Spector, Anne Chain, Elizabeth Smith, Hedy Teppler, Rohan Hazra, Kat Calabrese, Bobbie Graham, Stephanie Popson, Yvonne Bryson, Mark Mirochnick, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. Journal of Acquired Immune Deficiency Syndromes. 2020. 85: 626-634. PMID: 32925360Year
2022
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1097
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
Citation
Kamunkhwala Gausi, Lubbe Wiesner, Jennifer Norman, Carole L Wallis, Carolyne Onyango-Makumbi, Tsungai Chipato, David W Haas, Renee Browning, Nahida Chakhtoura, Grace Montepiedra, Lisa Aaron, Katie McCarthy, Sarah Bradford, Tichaona Vhembo, Lynda Stranix-Chibanda, Gaerolwe R Masheto, Avy Violari, Blandina T Mmbaga, Linda Aurpibul, Ramesh Bhosale, Neetal Nevrekhar, Vanessa Rouzier, Enid Kabugho, Mercy Mutambanengwe, Vongai Chanaiwa, Mandisa Nyati, Tsungai Mhembere, Fuanglada Tongprasert, Anneke Hesseling, Katherine Shin, Bonnie Zimmer, Diane Costello, Patrick Jean-Philippe, Timothy R Sterling, Gerhard Theron, Adriana Weinberg, Amita Gupta, Paolo Denti, IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical Pharmacology & Therapeutics. 2020. PMID: 32909316Year
2022
Journal
Clinical Pharmacology & Therapeutics
Study
P1078
The neovaginal microbiome of transgender women post-gender reassignment surgery
Citation
K Birse, K Kratzer, C Zuend, S Mutch, L Noel-Romas, A Lamont, M Abou, E Jalil, V Veloso, B Grinsztejn, R Friedman, K Broliden, F Bradley, V Poliquin, F Li, C Yanavich, A Burgener, G Aldrovandi. The neovaginal microbiome of transgender women post-gender reassignment surgery. BMC Microbiome. 2020. 8: 61. PMID: 32370783Year
2020
Journal
BMC Microbiome
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
Citation
Esaú C João, R Leavitt Morrison, David E Shapiro, Nahida Chakhtoura, Maria Isabel S Gouvèa, Maria de Lourdes B Teixeira, Trevon L Fuller, Blandina T Mmbaga, James S Ngocho, Boniface N Njau, Avy Violari, Ruth Mathiba, Zaakirah Essack , Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Pedro Cahn, Sinart Prommas , Timothy R Cressey, Kulkanya Chokephaibulkit, Peerawong Werarak, Lauren Laimon, Roslyn Hennessy , Lisa M Frenkel , Patricia Anthony, Brookie M Best, George K Siberry, Mark Mirochnick. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020. 7: e322-e331. PMID: 32386720Year
2020
Journal
Lancet HIV
Study
P1081
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)
Citation
Diana Clarke, Edward Acosta, Mae Cababasay, Jiajia Wang, Anne Chain, Hedy Teppler, Stephanie Popson, Bobbie Graham, Betsy Smith, Rohan Hazra, Kat Calabrese, Yvonne Bryson, Stephen Spector, Jos Lommerse, Mark Mirochnick, IMPAACT P1110 Protocol Team. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 2020. 84: 70-7. PMID: 31913995Year
2020
Journal
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Study
P1110
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women
Citation
Amita Gupta, Grace Montepiedra, Lisa Aaron, Gerhard Theron , Katie McCarthy , Sarah Bradford , Tsungai Chipato, Tichaona Vhembo, Lynda Stranix-Chibanda, Carolyne Onyango-Makumb, Gaerolwe R Masheto , Avy Violari, Blandina T Mmbaga, Linda Aurpibul, Ramesh Bhosale, Vidya Mave , V Rouzier, A Hesseling, K Shin, B Zimmer, D Costello, TR Sterling, N Chakhtoura, P Jean-Philippe, A Weinberg, P1078 TB APPRISE Study Team. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. New England Journal of Medicine. 2019. 381: 1333-1346. PMID: 31577875Journal
New England Journal of Medicine
Study
P1078
Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.
Citation
M McManus, J Henderson, A Gautam, R Brody, ER Weiss, D Persaud, E Mick, K Lazuriaga, PACTG 356 Investigators. Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.. Clinical Infectious Diseases. 2019. PMID: 30668843Year
2019
Journal
Clinical Infectious Diseases
Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe
Citation
L Stranix-Chibanda, S Brummel, J Pilotto, M Mutambanengwe, V Chanaiwa, T Mhembere, M Kamateeka, J Aizire, G Masheto, R Chamanga, M Maluwa, S Hanley, E Joao, G Theron, N Nevrekar, M Nyati, B Santos, L Aurpibul, M Mubiana-Mbewe, R Oliveira, T Anekthananon, P Mlay, K Angelidou, C Tierney, L Ziemba, A Coletti, K McCarthy, M Basar, N Chakhtoura, R Browning, J Currier, MG Fowler, P Flynn, PROMISE study team. Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe. AIDS and Behavior. 2019. 23: 2522-2531. PMID: 31399793Year
2019
Journal
AIDS and Behavior
Study
1077BF, 1077FF, 1077HS